Choi June Ho, Kang Hui Dong, Park Jin Hoon, Gu Bon Sub, Jung Sang Ku, Oh Se Hyun
Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Department of Emergency Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea.
Korean J Neurotrauma. 2017 Oct;13(2):130-136. doi: 10.13004/kjnt.2017.13.2.130. Epub 2017 Oct 31.
There are no strong guidelines on how long or how we should undertake conservative treatment during the acute period of an osteoporotic vertebral compression fracture (VCF).
We treated 202 patients with conservative treatment on VCF from March 2012 to August 2015. On inclusion criteria, 75 patients (22 males and 53 females) were included in the final analysis. After admission, a transdermal fentanyl patch with low dose (12.5 µg) application was attempted in all patients. In an unresponsive patient, the fentanyl patch was increased by 25 µg. After identifying the tolerable toilet ambulation of the patient without any assistance, hospital discharge was recommended. We classified two patient groups into one favorable group and one unfavorable group and compared several clinical and radiological factors.
Among 75 patients, the clinical outcome of 57 patients (76%) was favorable, but that of 18 patients (24%) was unfavorable. In clinical outcomes, the numeric rating scale at 6 and 12 months and Odom's criteria at 12 months was significantly different between the favorable and the unfavorable groups. The dose of the patches used showed statistically significant differences between the two groups (=0.001).
The only statistically significant affecting factor for an unfavorable outcome was the use of a higher dose fentanyl patch. Our data inferred that the unresponsiveness to a low-dose fentanyl patch could be helpful to select patients necessary for percutaneous vertebroplasty or kyphoplasty.
对于骨质疏松性椎体压缩骨折(VCF)急性期的保守治疗应持续多长时间以及采用何种方式进行,目前尚无强有力的指导原则。
2012年3月至2015年8月期间,我们对202例VCF患者进行了保守治疗。依据纳入标准,最终分析纳入了75例患者(22例男性和53例女性)。入院后,所有患者均尝试使用低剂量(12.5μg)的透皮芬太尼贴剂。对于无反应的患者,芬太尼贴剂剂量增加25μg。在确定患者无需任何协助即可耐受坐便及行走后,建议出院。我们将患者分为两组,一组为预后良好组,另一组为预后不良组,并比较了若干临床和影像学因素。
75例患者中,57例(76%)临床结局良好,18例(24%)临床结局不良。在临床结局方面,预后良好组与预后不良组在6个月和12个月时的数字评分量表以及12个月时的奥多姆标准存在显著差异。两组使用的贴剂剂量显示出统计学显著差异(=0.001)。
唯一对不良结局有统计学显著影响的因素是使用了更高剂量的芬太尼贴剂。我们的数据推断,对低剂量芬太尼贴剂无反应可能有助于筛选出需要进行经皮椎体成形术或后凸成形术的患者。